Patient-reported outcome instruments used in immune-checkpoint inhibitor clinical trials in oncology: a systematic review.

Sara Colomer-LahigueraDenise Bryant-LukosiusSarah RietkoetterLorraine MartelliKarin RibiDonna Fitzpatrick-LewisDiana SherifaliAngela OrcurtoRosalyn JuergensManuela Eicher

Published in: Journal of patient-reported outcomes (2020)

Despite the high frequency of symptom-related toxicities related to ICI, these events are only partially covered (or not addressed) by current PRO instruments, even when combined. Further research is needed to develop new strategies to tailor PRO instruments to specific ICI toxicities.

Keyphrases

patient reported outcomes
high frequency
clinical trial
transcranial magnetic stimulation
anti inflammatory
palliative care
open label
drug induced
phase ii